| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 06/20/2001 | CN1067275C Snow ganoderma lucidum oral liquid |
| 06/20/2001 | CN1067274C Snow ganoderma lucidum solid medicament |
| 06/20/2001 | CN1067268C Medicine for resisting renal failure |
| 06/19/2001 | US6248907 Alpha 1 and alpha 2 adrenoceptor antagonistic effects and urogenital selectivity; benign prostate hyperplasia; dibenzoyltartrate salt |
| 06/19/2001 | US6248901 Heterocyclic vinyl ethers |
| 06/19/2001 | US6248888 Heating 2-chloro-4-amino-6,7-dimethoxyquinazoline and 1-(2-tetrahydrofuroyl)piperazine in a polar organic reaction solution |
| 06/19/2001 | US6248785 IL-8 receptor antagonists |
| 06/19/2001 | US6248783 Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
| 06/19/2001 | US6248765 Imidazole derivatives as histamine receptor H3 (ANT) agonists |
| 06/19/2001 | US6248757 Antiserotonine agents |
| 06/19/2001 | US6248747 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248557 RatC |
| 06/19/2001 | US6248368 Administering magnesium salt |
| 06/19/2001 | US6248363 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents |
| 06/19/2001 | CA2218616C Nitrosylated neuropeptides |
| 06/19/2001 | CA2013893C Tetrahydrobenz¬c,d|indole serotonin agonists |
| 06/19/2001 | CA1341260C Pharmaceutical and/or dietary compsitions containing l-carnitine and l- lysine |
| 06/14/2001 | WO2001042484A1 Il-6 like polynucleotide |
| 06/14/2001 | WO2001042472A2 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 06/14/2001 | WO2001042368A1 Substituted phthalocyanines and their precursors |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042281A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | WO2001042244A1 Novel 1,8-naphthyridin-2(1h)-one derivatives |
| 06/14/2001 | WO2001042238A1 Heterocyclic derivatives |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001042213A1 Urea compounds having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042212A1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001041813A2 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001027101A3 Anhydrous salt |
| 06/14/2001 | WO2001017989A3 Heteroaryloxypropanolamines as beta3-adrenergic receptor agonists |
| 06/14/2001 | WO2001016133A3 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2396739A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | CA2394891A1 Substituted phthalocyanines and their precursors |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392740A1 Il-6 like polynucleotides, polypeptides, and antibodies |
| 06/14/2001 | CA2391944A1 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/13/2001 | EP1106615A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106210A2 Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| 06/13/2001 | EP1106179A2 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/13/2001 | EP1106176A1 Remedies for renal failure |
| 06/13/2001 | EP1105734A2 Homer interacting proteins |
| 06/13/2001 | EP1105504A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 06/13/2001 | EP1105389A1 Integrin receptor antagonists |
| 06/13/2001 | EP1105147A1 Methods for treatment of neurological disorders |
| 06/13/2001 | EP1105143A1 Human histone deacetylase gene hd4 |
| 06/13/2001 | EP1105133A1 Tricyclic compounds |
| 06/13/2001 | EP1105127A1 Treatment of fecal incontinence |
| 06/13/2001 | EP1105120A2 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| 06/13/2001 | EP1105111A1 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 06/13/2001 | EP0805812B1 Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonists |
| 06/13/2001 | EP0755382B1 Quinolone derivative for treatment of urinary incontinence |
| 06/13/2001 | EP0725798B1 Type i angiotensin ii receptor specific monoclonal antibodies and hybridoma |
| 06/13/2001 | CN1299342A Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents |
| 06/13/2001 | CN1299291A Implantable particles for tissue bulking and the treatment of gastroesophageal reflux diosease |
| 06/13/2001 | CN1299235A Novel composition of eprosartan |
| 06/13/2001 | CN1298719A Medicine for treating uninary calculaus and its preparing process |
| 06/13/2001 | CN1067075C Pyrrolo-gyrrolone used as neutrophil elastase inhibitor |
| 06/13/2001 | CN1067067C 杂环速激肽受体拮抗物 Heterocyclic tachykinin receptor antagonists |
| 06/13/2001 | CN1067065C (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate |
| 06/12/2001 | US6245811 Fatty acid esters as bioactive compounds |
| 06/12/2001 | US6245805 Coadministering a taxane and a cyclosporin |
| 06/12/2001 | US6245760 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 06/12/2001 | US6245526 Mammalian nucleotide sequences which code polypeptides for the classification, diagnosis, treatment, and prevention of cell proliferative and lipid defects |
| 06/10/2001 | CA2327946A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/10/2001 | CA2327925A1 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/07/2001 | WO2001040251A1 Transforming growth factor alpha hiii |
| 06/07/2001 | WO2001040249A1 Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | WO2001040231A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 06/07/2001 | WO2001040230A1 Pyrazolopyrazines and their use as adenosine antagonists |
| 06/07/2001 | WO2001040225A1 Remedies or preventives for frequent urination or urinary incontinence |
| 06/07/2001 | WO2001040217A1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 06/07/2001 | WO2001040216A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | WO2001039777A1 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
| 06/07/2001 | WO2001039723A2 Triazospiro compounds having nociceptin receptor affinity |
| 06/07/2001 | WO2001032865A8 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 06/07/2001 | WO2001007612A3 Receptors and associated proteins |
| 06/07/2001 | CA2393179A1 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
| 06/07/2001 | CA2392931A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | CA2392693A1 Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | CA2390839A1 Transforming growth factor alpha hiii |
| 06/07/2001 | CA2390786A1 Compositions and methods for the treatment of immune related diseases |
| 06/07/2001 | CA2327575A1 Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| 06/06/2001 | EP1104760A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104759A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |